RadioBDC Logo
| Listen Live
Text size +

Karuna Pharmaceuticals targeting schizophrenia with new discoveries licensed from Vanderbilt University

Posted by Scott Kirsner  September 20, 2011 02:53 PM

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Boston-based Karuna Pharmaceuticals is set to announce this week that it has licensed a set of scientific discoveries from Vanderbilt University's Center for Neuroscience Discovery. The start-up hopes to develop them into effective new drugs for schizophrenia, a disabling mental illness that affects more than 24 million people worldwide.

A problem with existing drugs for schizophrenia, explains Karuna chief executive Ed Harrigan, is that they only treat some of the symptoms of the disease. "Current drugs do a reasonable job with hallucinations and delusions. But they don't address some of the impairments of attention and memory, or the asociality and anhedonia that can accompany the disease. And those are all symptoms that can really block people from being reintegrated into society."

The family of chemical compounds that Karuna has licensed from Vanderbilt are called glycine transport inhibitors. Harrigan believes that they may be useful in addressing neurological signaling problems in the brains of schizophrenics. The hypothesis, he explains, is that there may be insufficient levels of the neurotransmitter glutamate in the synapses, or spaces between neurons, of people suffering from schizophrenia. Increasing the amount of glycine — another neurotransmitter — may dial up the effectiveness of the glutamate that is present.

Karuna is also developing another treatment for schizophrenia, based on a drug that is no longer patented. (The company has made modifications and applied for a new patent.) Harrigan, formerly a senior licensing executive at Pfizer, says both programs "have the potential to be a breakthrough treatment." The off-patent drug has already been through clinical trials, and Karuna may soon begin trials of its own. The compounds licensed from Vanderbilt have not yet been tested in humans.

Karuna is set up as a "virtual" pharma company, with a handful of employees working with a network of outside service providers to shepherd along promising chemical compounds, perhaps to the point where they'll be acquired or licensed by larger entities. (Virtual pharmas typically don't have their own labs, or plans to set up manufacturing facilities.) Harrigan works in Waterford, Connecticut, and the company has office space that it shares with Puretech Ventures, the Boston venture firm that helped form Karuna. The company, formed in January, has received about $1.5 million in seed funding so far, and Harrigan says it may soon raise more: "We're talking to a number of potential funding sources."

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article



BetaBoston technology news logo
Innovation and technology news that matters, on a new website from the Boston Globe, featuring Scott Kirsner and other original reporting.

About Scott Kirsner

Scott Kirsner was part of the team that launched in 1995, and has been writing a column for the Globe since 2000. His work has also appeared in Wired, Fast Company, The New York Times, BusinessWeek, Newsweek, and Variety. Scott is also the author of the books "Fans, Friends & Followers" and "Inventing the Movies," was the editor of "The Convergence Guide: Life Sciences in New England," and was a contributor to "The Good City: Writers Explore 21st Century Boston." Scott also helps organize several local events on entrepreneurship, including the Nantucket Conference and Future Forward. Here's some background on how Scott decides what to cover, and how to pitch him a story idea.

On Facebook

Subscribe via e-mail

Get Innovation Economy updates via e-mail. Enter your address and click 'Subscribe':

More from Scott


March 3: Web Innovators Group
Demos, drinks, and schmoozing at the Royal Sonesta in Cambridge.

March 7-8: MassDigi Game Challenge
Competition for aspiring game developers... plus panels and keynotes related to the business of play.

April 3-4: Mass Biotech Annual Meeting
Issues facing the region's life sciences community.